Website: covalx.com | LinkedIn: linkedin.com/company/covalx
Seeing Exactly Where Antibodies Bind
How CovalX uses mass spectrometry to map epitopes and protein interactions with precision
At a glance
- Company: CovalX (covalx.com)
- Origins: Spun out of ETH Zurich (the Swiss Federal Institute of Technology) in 2005
- Focus: Mass spectrometry-based epitope mapping and protein interaction analysis for biotherapeutics
- Business model: Specialized CRO services, plus proprietary cross-linking reagents and High-Mass MALDI technology
- Working with PSG on: Sales and business development scaling
Born at ETH Zurich, built on patented technology
CovalX began as a spin-off from ETH Zurich, founded to commercialize a patented mass spectrometry platform for analyzing protein-protein interactions directly in solution: High-Mass MALDI.
Conventional mass spectrometry struggles to detect large, non-covalent protein complexes intact. CovalX solved that by combining specially developed cross-linking chemistry with high-mass detection, so complexes from 1 to 2,000 kDa can be measured whole, unfragmented, and with their stoichiometry confirmed.
Two decades later, that foundation powers one of the industry’s most specialized CRO services for antibody and protein characterization.
Two complementary epitope mapping methods
Knowing exactly where an antibody binds matters for patent protection, mechanism of action, regulatory filings, and choosing between candidates. CovalX offers two complementary mass spectrometry approaches, which can run side by side in a single project:
- Cross-Linking Mass Spectrometry (XL-MS): CovalX’s patented approach maps both the epitope on the antigen and the paratope on the antibody from a single experiment. It works for linear and conformational epitopes, on antigens of any molecular weight
- Hydrogen-Deuterium Exchange MS (HDX-MS): runs on the latest automation, LC systems, and analysis software for peptide-level binding information
Every project starts the same way: High-Mass MALDI analysis of the intact proteins and the antibody-antigen complex, which confirms the complex is really there before any mapping begins. It’s a built-in quality check that sets CovalX’s workflow apart.
Validated against the gold standard
CovalX has benchmarked its XL-MS method against X-ray crystallography, mapping the conformational epitopes of approved checkpoint antibodies Ipilimumab, Nivolumab, and Pembrolizumab. In 2025, research from Merck highlighted the advantages of using CovalX’s cross-linking data for epitope mapping.
Most XL-MS epitope mapping projects deliver in four to five weeks, with rush options available.
Beyond epitopes
- Protein complex analysis: intact detection of non-covalent complexes, aggregation, and stoichiometry
- Antibody characterization: antigen binding and multi-binding assays
- XL-IP-MS: an expanded 2026 service that combines cross-linking with immunoprecipitation mass spectrometry
- Reagents and kits: proprietary cross-linking kits for in-house protein complex analysis